| 引用本文: | 陈丽坪,吴燕,金澄滔,吴圣洁.新型冠状病毒肺炎患者抗病毒治疗的药学监护：基于试行第七版诊疗方案[J].中国现代应用药学,2020,37(5):549-554. |
| CHEN Liping,WU Yan,JIN Chengtao,WU Shengjie.Pharmaceutical Care of Antiviral Drugs in COVID-19 Patients: Based on Diagnosis and Treatment Scheme(Trial Version 7)[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(5):549-554. |
|
| 摘要: |
| 合并基础疾病的新型冠状病毒肺炎患者用药较多，为尽可能减少药物间的相互作用、提升药物治疗效果、减少患者药物不良反应发生率，本文对国家卫生健康委员会《新型冠状病毒肺炎诊疗方案（试行第七版）》纳入的抗病毒药物与其他治疗药物之间可能存在的药物相互作用进行阐述，并提供药学监护建议，以期为临床合理用药提供建议。 |
| 关键词: 新型冠状病毒肺炎 基础疾病 药物相互作用 药学监护 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.05.006 |
| 分类号:R969.3 |
| 基金项目:浙江省医药卫生科技项目青年人才项目（2019RC190）；浙江省药学会医院药学专项科研资助项目（2017ZYY08，2017ZYY09） |
|
| Pharmaceutical Care of Antiviral Drugs in COVID-19 Patients: Based on Diagnosis and Treatment Scheme(Trial Version 7) |
|
CHEN Liping, WU Yan, JIN Chengtao, WU Shengjie
|
|
Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China
|
| Abstract: |
| The patients with both COVID-19 and basic diseases have to take multiple medications. In order to reduce the drug interaction, improve the effect of medical treatment, and reduce the incidence of adverse drug reactions in patients, the drug interactions between antiviral drugs included in the National Health and Health Commission’s Diagnostic and Treatment Scheme for COVID-19(Trial Version 7) and other therapeutic drugs are elaborated in this article. Based on this, this article also offer a proposal on pharmaceutical care, hoping to provide medication advice for the rational clinical treatment. |
| Key words: COVID-19 basic diseases drug-drug interaction pharmaceutical care |
